DSM-Firmenich AG (DSMFF)
| Market Cap | 29.64B +43.4% |
| Revenue (ttm) | 10.35B +10.1% |
| Net Income | -1.61B |
| EPS | -6.24 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 26.40 |
| Dividend | 2.94 (2.54%) |
| Ex-Dividend Date | May 11, 2026 |
| Volume | 1,752 |
| Open | 116.00 |
| Previous Close | 109.98 |
| Day's Range | 116.00 - 116.00 |
| 52-Week Range | 67.00 - 116.00 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 18, 2027 |
About DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through Perfumery & Beauty; Taste, Texture & Health; and Health, Nutrition & Care segments. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes,... [Read more]
News
DSM-Firmenich price target raised to EUR 75 from EUR 68 at JPMorgan
JPMorgan raised the firm’s price target on DSM-Firmenich (DSMFF) to EUR 75 from EUR 68 and keeps an Underweight rating on the shares.
DSM-Firmenich AG Earnings Call Transcript: Q3 2026
Q3 organic growth was 5% and EBITDA margin rose to 20.4%; the 2026 growth outlook was raised. Management reaffirmed 2027-2028 growth and margin ambitions, supported by cost actions and a strong innovation pipeline.
DSM-Firmenich AG Earnings release: Q3 2026
DSM-Firmenich AG released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Dsm-firmenich posts Q3 results slightly above expectations, raises growth outlook
Dsm-firmenich reported third-quarter core profit a touch above market expectations on Wednesday, citing more contract wins, and raised its full-year growth outlook but failed to impress investors.
dsm-firmenich reports Q3 2026 trading update
Press Release Ad hoc announcement pursuant to article 53 LR Kaiseraugst (Switzerland), Maastricht (Netherlands), November 4, 2026 dsm-firmenich reports Q3 2026 trading update Good top-line growth with...
DSM-Firmenich AG - Depositary Receipt Price Target Increased by 20.56% to $11.19
The average one-year price target for DSM-Firmenich AG - Depositary Receipt (OTCPK:DSFIY) (DB:ZX61) has been revised to $11.19 / share. This is an increase of 20.56% from the prior estimate of $9.28 d...
DSM-Firmenich downgraded to Neutral from Outperform at BNP Paribas
BNP Paribas analyst Nicola Tang downgraded DSM-Firmenich (DSMFF) to Neutral from Outperform with a EUR 100 price target
DSM-Firmenich price target raised to EUR 111 from EUR 106 at Citi
Citi raised the firm’s price target on DSM-Firmenich (DSMFF) to EUR 111 from EUR 106 and keeps a Buy rating on the shares.
DSM-Firmenich downgraded to Neutral from Buy at Rothschild & Co Redburn
Rothschild & Co Redburn analyst Artem Chubarov downgraded DSM-Firmenich (DSMFF) to Neutral from Buy with a EUR 93 price target
DSM-Firmenich price target raised to EUR 90 from EUR 85 at Morgan Stanley
Morgan Stanley analyst Lisa De Neve raised the firm’s price target on DSM-Firmenich (DSMFF) to EUR 90 from EUR 85 and keeps an Equal Weight rating on the shares. Published…
India investigates fragrance giants over price collusion, document shows
Global fragrance makers Givaudan , Firmenich and International Flavors & Fragrances face a second antitrust investigation by Indian authorities, according to a regulatory document seen by Reuters.
DSM-Firmenich price target raised to EUR 106 from EUR 99 at Citi
Citi raised the firm’s price target on DSM-Firmenich (DSMFF) to EUR 106 from EUR 99 and keeps a Buy rating on the shares.
DSM-Firmenich price target raised to EUR 68 from EUR 60 at JPMorgan
JPMorgan raised the firm’s price target on DSM-Firmenich (DSMFF) to EUR 68 from EUR 60 and keeps an Underweight rating on the shares.
Dsm-firmenich's fragrance-led core profit beat sends shares higher
Dsm-firmenich on Thursday beat market expectations for second-quarter core earnings and said full-year sales growth should reach the upper end of its target range on the back of broad-based volume gr...
DSM-Firmenich AG Earnings Call Transcript: Q2 2026
Strong H1 and Q2 results with robust sales and EBITDA growth, margin improvement, and solid cash generation. Outlook for 2026 is reaffirmed, with cost programs and innovation pipeline supporting future growth, while FX headwinds and restocking effects are closely monitored.
DSM-Firmenich AG Slides: Q2 2026
DSM-Firmenich AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
DSM-Firmenich AG Earnings release: Q2 2026
DSM-Firmenich AG released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
DSM-Firmenich initiated with an Outperform at Bernstein
Bernstein initiated coverage of DSM-Firmenich (DSMFF) with an Outperform rating and EUR 103 price target The firm says that after 15 years of market outperformance versus chemicals, sector rotation an...
DSM-Firmenich price target raised to EUR 98 from EUR 75 at Deutsche Bank
Deutsche Bank raised the firm’s price target on DSM-Firmenich (DSMFF) to EUR 98 from EUR 75 and keeps a Buy rating on the shares.
DSM-Firmenich price target raised to EUR 99 from EUR 87 at Citi
Citi analyst Sebastian Satz raised the firm’s price target on DSM-Firmenich (DSMFF) to EUR 99 from EUR 87 and keeps a Buy rating on the shares.
DSM-Firmenich price target raised to EUR 73 from EUR 71 at Morgan Stanley
Morgan Stanley analyst Lisa De Neve raised the firm’s price target on DSM-Firmenich (DSMFF) to EUR 73 from EUR 71 and keeps an Equal Weight rating on the shares. Published…
dsm-firmenich receives FDA approval on PARSOL® Shield, a new sun protection ingredient for the U.S.
Press Release dsm-firmenich receives FDA approval on PARSOL® Shield, a new sun protection ingredient for the U.S. Kaiseraugst (Switzerland), Maastricht (Netherlands), June 10, 2026 dsm-firmenich, inno...
DSM-Firmenich downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs downgraded DSM-Firmenich (DSMFF) to Sell from Neutral with a price target of EUR 65, down from EUR 75. The firm made seven rating changes in European chemicals, “positioning…
DSM-Firmenich price target raised to EUR 71 from EUR 69 at Morgan Stanley
Morgan Stanley analyst Lisa De Neve raised the firm’s price target on DSM-Firmenich (DSMFF) to EUR 71 from EUR 69 and keeps an Equal Weight rating on the shares. Published…
DSM-Firmenich price target lowered to EUR 60 from EUR 70 at JPMorgan
JPMorgan lowered the firm’s price target on DSM-Firmenich (DSMFF) to EUR 60 from EUR 70 and keeps an Underweight rating on the shares.